Melanocortin Receptor Agonists
Bremelanotide
Also known as PT-141 · Vyleesi
FDA-approved for specific indicationsFDA-approved
Last reviewed: 2026-11-19
Overview
Regulatory status
FDA approval applies only to the named products and indications below. It does not approve every formulation or other use.
Vyleesi · Sexual Health
Acquired, generalized hypoactive sexual desire disorder in premenopausal women, with distress and specified exclusions; not sexual-performance enhancement.
Authoritative label record
Status as of 2026-11-19. Regulations change. Check FDA.gov for current information.
WADA prohibited status: current list and contextEvidence at a glance
Two phase 3 trials supported a narrowly defined indication; no general performance or male sexual-health approval follows.
Key sources
Indication-specific regulatory sources and editorial screen checked November 19, 2026. This is not an exhaustive systematic review; consult current labels.